Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma – PR Newswire

by

  1. Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma PR Newswire
  2. Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy – TipRanks.com TipRanks
  3. Delcath Systems Stock Is Rocketing Higher: What’s Going On? – Delcath Systems (NASDAQ:DCTH) Benzinga
  4. Why Is Delcath Systems (DCTH) Stock Up 72% Today? InvestorPlace
  5. Persistence pays for Delcath as cancer treatment Hepzato Kit finally scores FDA nod FiercePharma
  6. View Full Coverage on Google News

Read original article here

Leave a Comment